Edition:
United Kingdom

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

10.45USD
8:59pm GMT
Change (% chg)

$-1.29 (-10.99%)
Prev Close
$11.74
Open
$11.80
Day's High
$12.19
Day's Low
$10.33
Volume
41,245
Avg. Vol
17,351
52-wk High
$15.70
52-wk Low
$5.28

Latest Key Developments (Source: Significant Developments)

Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME.OVID THERAPEUTICS INC - HAVE RAPIDLY ADVANCED TAK-935/OV935 PROGRAM INTO A PHASE 1B/2A CLINICAL TRIAL AND ANTICIPATE DATA IN 2018.  Full Article

Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS.OVID THERAPEUTICS INC - ‍ANTICIPATES DATA FROM STARS TRIAL TO BE AVAILABLE IN SECOND HALF OF 2018​.OVID THERAPEUTICS INC - ‍RESULTS FROM PHASE 1 CLINICAL TRIAL OF ADOLESCENTS WITH ANGELMAN AND FRAGILE X SYNDROMES DEMONSTRATED OV101 WAS WELL TOLERATED​.OVID THERAPEUTICS INC - ‍IN TRIAL, OV101 WAS FOUND TO BE GENERALLY SAFE AND WELL TOLERATED​.  Full Article

Ovid Therapeutics Q3 loss per share $0.38
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ovid Therapeutics Inc ::Ovid Therapeutics reports third quarter 2017 financial results and corporate progress.Q3 loss per share $0.38.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Ovid Therapeutics Inc - ‍cash and cash equivalents $96 million as at Sept 30 , 2017 versus $51.9 million as at Dec 31, 2016​.  Full Article

Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Ovid Therapeutics Inc :Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies.  Full Article

Ovid Therapeutics Q1 loss per share $3.48
Tuesday, 13 Jun 2017 

June 13 (Reuters) - Ovid Therapeutics Inc ::Ovid Therapeutics reports first quarter 2017 financial results and recent corporate progress.Q1 loss per share $3.48.Q1 earnings per share view $-0.87 -- Thomson Reuters I/B/E/S.Ovid Therapeutics Inc says company expects topline data to evaluate ov101 to be available in second half of 2017..  Full Article

BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME